{
    "body": "PBT2 has been tested for which disorder?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21797865", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18953111", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21739113", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20164561", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22403554", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18625454", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16370917", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19742190", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22592705", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20545360", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22747493", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21232050", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18672400", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21504115"
    ], 
    "ideal_answer": [
        "PBT2 has been tested for treatment of Alzheimer's disease."
    ], 
    "exact_answer": [
        "Alzheimer's disease"
    ], 
    "type": "factoid", 
    "id": "54fc91e96ad7dcbc12000001", 
    "snippets": [
        {
            "offsetInBeginSection": 2876, 
            "offsetInEndSection": 2998, 
            "text": "PBT2 improved cognition in a phase II clinical trial with AD patients, and further clinical testing is currently underway.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22747493", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 2223, 
            "offsetInEndSection": 2402, 
            "text": "In the second trial a successor compound, PBT2, was compared with placebo in 78 participants with mild Alzheimer's dementia; all were included in the intention-to-treat analysis. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22592705", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 3614, 
            "offsetInEndSection": 3795, 
            "text": "The second trial of PBT2 was more rigorously conducted and showed that after 12 weeks this compound appeared to be safe and well tolerated in people with mild Alzheimer's dementia. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22592705", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 552, 
            "offsetInEndSection": 830, 
            "text": "The purpose of this mini-review is to highlight the emerging notion that metal chaperones, such as PBT2 (Prana Biotechnology), modulate a variety of critical pathways affecting key aspects of the AD cascade to provide a more \"holistic\" approach to the treatment of this disease.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22403554", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 120, 
            "text": "The Alzheimer's therapeutic PBT2 promotes amyloid-\u03b2 degradation and GSK3 phosphorylation via a metal chaperone activity.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21797865", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 157, 
            "offsetInEndSection": 271, 
            "text": "The leading compound in this class of therapeutic, PBT2, improved cognition in a clinical trial with AD patients. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21797865", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1305, 
            "offsetInEndSection": 1477, 
            "text": "Intracellular translocation of Zn and Cu via the metal chaperone activity of PBT2 may be an important mechanism by which PBT2 improves cognitive function in people with AD.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21797865", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1056, 
            "offsetInEndSection": 1208, 
            "text": "Metalloproteinase modifiers such as PBT2 may be useful AD therapies, but current evidence gives no support to their immediate use in pre-symptomatic AD.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21739113", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1212, 
            "offsetInEndSection": 1401, 
            "text": "The most advanced of these strategies is the so-called 'metal protein attenuating compound' approach, with the lead molecule PBT2 having successfully completed early phase clinical trials. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21232050", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 85, 
            "text": "PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20164561", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 108, 
            "offsetInEndSection": 448, 
            "text": " A recent Phase IIa double-blind, randomized, placebo-controlled trial found that the 250 mg dose of PBT2 was well-tolerated, significantly lowered cerebrospinal fluid (CSF) levels of amyloid-beta42, and significantly improved executive function on a Neuro-psychological Test Battery (NTB) within 12 weeks of treatment in patients with AD. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20164561", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1346, 
            "offsetInEndSection": 1415, 
            "text": "These findings further encourage larger-scale testing of PBT2 for AD.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20164561", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 94, 
            "offsetInEndSection": 222, 
            "text": "Recently, CQ and its analog PBT2 have shown encouraging effects in the animal and clinical trials for Alzheimer's disease (AD). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21504115", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 841, 
            "offsetInEndSection": 1092, 
            "text": "Experimental treatments potentially useful for Alzheimer's disease include dimebon, PBT2 and etanercept; the safety and efficacy of the Alzheimer's vaccine remains to be proven, and growth hormone secretagogue and tarenflurbil are likely ineffective. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19742190", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 257, 
            "text": "The recent report of positive results from a Phase IIa clinical trial of PBT2, a novel drug that targets amyloid-beta-metal interactions, underscores the value of abnormal transition metal metabolism as a potential therapeutic target in Alzheimer's disease.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18953111", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1260, 
            "offsetInEndSection": 1418, 
            "text": "It has performed very satisfactorily in toxicology and Phase I clinical trials and is advancing as a disease-modifying candidate drug for Alzheimer's disease.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18953111", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 2631, 
            "offsetInEndSection": 2799, 
            "text": "Future trials that are larger and longer will establish if the effects of PBT2 on biomarkers and cognition that are reported here translate into clinical effectiveness.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18672400", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1364, 
            "offsetInEndSection": 1588, 
            "text": "Small molecules targeting Abeta-metal interactions (e.g., PBT2) are currently advancing through clinical trials and show increasing promise as disease-modifying agents for Alzheimer's disease based on the \"metal hypothesis.\"", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18625454", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1315, 
            "offsetInEndSection": 1487, 
            "text": "Intracellular translocation of Zn and Cu via the metal chaperone activity of PBT2 may be an important mechanism by which PBT2 improves cognitive function in people with AD.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21797865", 
            "endSection": "abstract"
        }
    ]
}